Low-dose Growth Hormone Investigated for Insulin Sensitivity, Steroid Metabolism in Obese PCOS Women
Background
Polycystic ovary syndrome (PCOS) is a prevalent and complex endocrine disorder strongly associated with obesity, increased visceral adiposity, and significant insulin resistance. Current therapeutic approaches, including lifestyle modifications and off-label use of metformin, often yield only modest and unsustained weight loss, proving insufficient to reverse the underlying obesity-driven pathophysiology. Growth hormone (GH), primarily through its stimulation of free 'bioavailable' insulin-like growth factor (IGF-I), is hypothesized to enhance insulin sensitivity and improve the overall metabolic profile in women afflicted with PCOS. This study specifically aims to unravel the precise mechanisms by which low-dose GH treatment influences the body's response to insulin, as well as its effects on steroid hormone metabolism, including cortisol clearance and testosterone levels, in obese PCOS patients.
Study Design
This is a randomized, quadruple-blinded, crossover clinical trial designed to investigate the effects of low-dose GH in obese PCOS women. Eligible participants, not recently on GH treatment, will be randomized to receive either daily low-dose GH or placebo injections for an initial 12-week period. Following a 4-week washout phase, subjects will crossover to the alternate treatment arm for another 12 weeks. Comprehensive assessments will be conducted before, during, and after each treatment phase. These include scans to quantify whole-body, abdominal, muscle, and liver fat, along with blood tests to measure cortisol levels and insulin sensitivity. Fat biopsies will also be analyzed for IGF-I density. Insulin sensitivity will be a key endpoint, measured at all four visits to the Oregon Clinical and Translational Research Institute (OCTRI).
Why It Matters
Elucidating the precise mechanisms by which low-dose GH influences insulin sensitivity and steroid metabolism in obese PCOS women could revolutionize therapeutic strategies. If the study hypothesis is confirmed, this research could offer a novel, targeted approach beyond the current limitations of metformin and lifestyle interventions, potentially leading to significant improvements in metabolic health and hormonal balance for this patient population. The robust crossover design and detailed mechanistic assessments are critical for translating these findings into a practical, usable clinical protocol. This study's outcomes could directly inform future dosing regimens, optimal timing, and potential combination therapies for GH in PCOS, moving towards more personalized and effective interventions for the complex metabolic dysfunction associated with the syndrome.
growth hormone
pcos
obesity
insulin resistance
metabolic syndrome
clinical trial